We Offer Worldwide Shipping
Login Wishlist

D-Mannose

$43

  • Brand : BIOFRON

  • Catalogue Number : BF-D2025

  • Specification : 98%

  • CAS number : 3458-28-4

  • Formula : C6H12O6

  • Molecular Weight : 180.156

  • PUBCHEM ID : 24749

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-D2025

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

180.156

Appearance

White crystalline powder

Botanical Source

Citrus reticulata

Structure Type

Carbohydrates

Category

Standards;Natural Pytochemical;API

SMILES

Synonyms

D(+)-Maltose/alpha-D-mannose/(+)-Mannose/D-MAN/(2S,3S,4R,5R)-2,3,4,5,6-Pentahydroxyhexanal/Mannose/(2R,3R,4S,5S)-2,3,4,5,6-pentahydroxyhexanal/D-(+)-Mannose,D-Mannopyranose/CARUBINOSE/Mannose, D-/D-(+)-Mannose/aldehydo-D-mannose/L-(-)-Mannose/aldehydo-D-manno-hexose/D-mannose/D-MANOSE/D(+)-Mannose/MANNOSE,D-(+)/D-Mannopyranose/d-mannos/D-(+)-Maose/SEMINOSE

IUPAC Name

Density

1.6±0.1 g/cm3

Solubility

Water; DMSO

Flash Point

286.7±26.6 °C

Boiling Point

527.1±50.0 °C at 760 mmHg

Melting Point

133-140ºC

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2940000000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:3458-28-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

23633128

Abstract

Purpose: To test whether D-mannose powder is effective for recurrent urinary tract infection (UTI) prevention.
Materials and methods: After initial antibiotic treatment of acute cystitis, 308 women with history of recurrent UTI and no other significant comorbidities were randomly allocated to three groups. The first group (n = 103) received prophylaxis with 2 g of D-mannose powder in 200 ml of water daily for 6 months, the second (n = 103) received 50 mg Nitrofurantoin daily, and the third (n = 102) did not receive prophylaxis.
Results: Overall 98 patients (31.8%) had recurrent UTI: 15 (14.6) in the D-mannose group, 21 (20.4) in Nitrofurantoin group, and 62 (60.8) in no prophylaxis group, with the rate significantly higher in no prophylaxis group compared to active groups (P < 0.001). Patients in D-mannose group and Nitrofurantoin group had a significantly lower risk of recurrent UTI episode during prophylactic therapy compared to patients in no prophylaxis group (RR 0.239 and 0.335, P < 0.0001). In active groups, 17.9% of patients reported side effects but they were mild and did not require stopping the prophylaxis. Patients in D-mannose group had a significantly lower risk of side effects compared to patients in Nitrofurantoin group (RR 0.276, P < 0.0001), but the clinical importance of this finding is low because Nitrofurantoin was well tolerated.
Conclusions: In our study, D-mannose powder had significantly reduced the risk of recurrent UTI which was no different than in Nitrofurantoin group. More studies will be needed to validate the results of this study, but initial findings show that D-mannose may be useful for UTI prevention.

Title

D-mannose Powder for Prophylaxis of Recurrent Urinary Tract Infections in Women: A Randomized Clinical Trial

Author

Bojana Kranjcec 1 , Dino Papeš, Silvio Altarac

Publish date

2014 Feb

PMID

30412675

Abstract

Aim: Urinary tract infections (UTIs) are increasingly antibiotic resistant, and alternate or adjunct therapies are urgently needed. Several studies suggest that D-mannose ingestion and a hypothesized increase in urinary D-mannose reduce UTI frequency. Our goal was to develop a reliable assay for urinary D-mannose, which is needed to assess the effects of supplemental D-mannose on urinary D-mannose and UTIs.
Results: We developed an enzymatic assay for D-mannose in urine. Hexoses in urine were phosphorylated, sequentially isomerized and oxidized, and the increases in reduced NADPH were measured in a spectrophotometer. Urinary mannose from ten volunteers was well above the detection limit and ranged from 8 to 700 μM.
Conclusion: A rapid, reliable, and sensitive assay was developed, readily detected urinary D-mannose, and is adaptable to high-throughput analysis. If urinary D-mannose is shown to correlate with susceptibility to UTIs, then the assay could assess susceptibility to UTIs and direct mannose therapy.

Title

Enzymatic Assay of D-mannose From Urine

Author

Iti Mehta 1 , Philippe Zimmern 2 , Larry Reitzer 1

Publish date

2018 Dec

PMID

28092855

Abstract

Several metabolites in human serum have been identified as potential cancer biomarkers for early detection. This study focuses on the LC-MS/MS method development and validation of d-mannose in human serum. Surrogate blank serum, coupled with stable isotope d-mannose-13C6, as internal standard, was used for generating standard curves ranging from 1 to 50μg/mL. Separation was achieved by an Agilent 1200 series HPLC equipped with a SUPELCOGELTM Pb, 6% Crosslinked column with HPLC water as a mobile phase at flow rate of 0.5mL/min at 80°C. Mass detection was performed under negative ionization electrospray. Inter- and intra-day accuracy and precision were <2%. The extraction recovery and matrix effect were 104.1%-105.5% and 97.0%-100.0%, respectively. This method was successfully applied for the quantification of d-mannose in the serum samples of 320 esophageal cancer patients and 323 healthy volunteers. We report a simple, specific and reproducible LC-MS/MS method for the quantification of d-mannose in human serum as a potential cancer biomarker.

KEYWORDS

Biomarker; Esophageal cancer; LC-MS/MS; Mannose; Serum.

Title

LC-MS/MS Determination of D-Mannose in Human Serum as a Potential Cancer Biomarker

Author

Lyndsey White 1 , Jing Ma 1 , Su Liang 1 , Beatriz Sanchez-Espiridion 2 , Dong Liang 3

Publish date

2017 Apr 15


Description :

D-Mannose is a carbohydrate, which plays an important role in human metabolism, especially in the glycosylationof specific proteins.